A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.